Aura Biosciences - AURA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.00
  • Forecasted Upside: 190.06%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$7.24
▲ +0.1 (1.40%)

This chart shows the closing price for AURA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aura Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AURA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AURA

Analyst Price Target is $21.00
▲ +190.06% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Aura Biosciences in the last 3 months. The average price target is $21.00, with a high forecast of $23.00 and a low forecast of $19.00. The average price target represents a 190.06% upside from the last price of $7.24.

This chart shows the closing price for AURA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Aura Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/13/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2023BTIG ResearchLower TargetBuy ➝ Buy$38.00 ➝ $21.00Low
11/10/2023JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$21.00 ➝ $19.00Low
7/27/2023ScotiabankInitiated CoverageSector Outperform$23.00Low
5/12/2023JMP SecuritiesLower Target$25.00 ➝ $24.00Low
3/16/2023JMP SecuritiesLower TargetOutperform$30.00 ➝ $25.00Low
11/11/2022JMP SecuritiesBoost TargetMarket Outperform$26.00 ➝ $30.00Low
7/19/2022JMP SecuritiesInitiated CoverageOutperformLow
11/23/2021SVB LeerinkInitiated CoverageOutperform$40.00High
11/23/2021BTIG ResearchInitiated CoverageBuy$38.00High
11/23/2021CowenInitiated CoverageOutperformHigh
11/23/2021Evercore ISIInitiated CoverageOutperform$35.00High
(Data available from 6/13/2019 forward)

News Sentiment Rating

1.17 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/16/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/15/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/14/2024
  • 6 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/13/2024

Current Sentiment

  • 6 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Aura Biosciences logo
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $7.24
Low: $7.20
High: $7.54

50 Day Range

MA: $7.34
Low: $6.95
High: $7.89

52 Week Range

Now: $7.24
Low: $5.99
High: $12.86

Volume

121,311 shs

Average Volume

167,812 shs

Market Capitalization

$358.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.37

Frequently Asked Questions

What sell-side analysts currently cover shares of Aura Biosciences?

The following Wall Street analysts have issued research reports on Aura Biosciences in the last year: BTIG Research, JMP Securities, and Scotiabank.
View the latest analyst ratings for AURA.

What is the current price target for Aura Biosciences?

3 Wall Street analysts have set twelve-month price targets for Aura Biosciences in the last year. Their average twelve-month price target is $21.00, suggesting a possible upside of 190.1%. Scotiabank has the highest price target set, predicting AURA will reach $23.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $19.00 for Aura Biosciences in the next year.
View the latest price targets for AURA.

What is the current consensus analyst rating for Aura Biosciences?

Aura Biosciences currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AURA will outperform the market and that investors should add to their positions of Aura Biosciences.
View the latest ratings for AURA.

What other companies compete with Aura Biosciences?

How do I contact Aura Biosciences' investor relations team?

The company's listed phone number is 617-500-8864 and its investor relations email address is [email protected]. The official website for Aura Biosciences is www.aurabiosciences.com. Learn More about contacing Aura Biosciences investor relations.